Terms and conditions

These Terms and Conditions, together with the Grant and any additional requirements outlined in the Grant Award Letter, form the full agreement between the Host Institution and Blood Cancer UK for the clinical improvement grant. They replace any previous agreements related to this grant.

Blood Cancer UK reserves the right to amend these Terms and Conditions at any time. Any changes will be communicated to you directly.

BC Lead Grant – Grants awarded under a Grant Award Letter issued on or after 1 January 2023.

Blood Cancer UK – A charity registered in England and Wales (no. 216032) and Scotland (no. SC037529), and a company limited by guarantee registered in England & Wales (no. 738089), whose registered office is: 5-11 Theobalds Road, London, WC1X 8SH. The correspondence is: Blood Cancer UK, Suite 31, Bonnington Bond, 2 Anderson Place, Edinburgh, EH6 5NP.

Equipment – The equipment required to conduct the improvement initiative.

Funded Intellectual Property – All present and future inventions discoveries, materials, technologies, products, data, algorithms, software, patents, databases, copyright, confidential information and other intellectual property and know-how arising from the Research and all other rights or forms of protection of a similar nature having equivalent effect anywhere in the world.

Funded Materials – Materials arising from Results.

Grant – The funding award made for the clinical improvement innovation and described in the Grant Award Letter.

Grant Award Letter – The letter from Blood Cancer UK to the grant holder specifying the amount of the grant and confirming the financial value award of the grant in GBP.

Grant holder – The lead applicant as specified in the Grant Award Letter.

Grant Period – The duration of the grant as set out in the Grant Award Letter.

Host Institution – The Hospital who the Grant is awarded to. They must be the employing organisation of the grant holder, unless specified in the award letter.

Indemnified Parties – Blood Cancer UK, its staff and agents.

Indirect Costs – Non-specific costs charged across all projects. They include the costs of the Host Institution’s administration such as human resources, finance, library and departmental services.

Institution Sanctions – The sanctions Blood Cancer UK may take against a host institution if the circumstances set out in clause 15.7 in the grant award letter should arise.

Intellectual Property Rights – All present and future rights arising from inventions, discoveries and other developments resulting from the research undertaken as a result of Blood Cancer UK funding including (without limitation) patents, design rights, copyright, database rights, moral rights, trademarks, service marks, know-how, confidential information and all other rights or forms of protection of a similar nature having equivalent effect anywhere in the world.

Know-how – All information which is not in the public domain, including that comprised in or derived from data, disks, tapes, manuals, source codes, flow-charts, catalogues and instructions.

Party and the Parties – Blood Cancer UK and/or the host Institution as appropriate.

Premises – All facilities where the project is conducted.

Clinical improvement initiative - The research and innovation that is the subject of the Grant.

Grant Personnel – The host Institution staff who are to be supervised by the grant holder to carry out the clinical improvement.